Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Infiltration vs Systemic Analgesia for ESWL
NCT06462573Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection and Lidocaine Hydrochloride Injection, without epinephrine in nephrolithiasis and ureteral calculus (2 arms), sponsored by Assiut University. Primary endpoint: Comparison between local and systemic analgesia. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injectionLidocaine Hydrochloride Injection, without epinephrine
03
Conditions
nephrolithiasisureteral calculus
Beyond the preview
Go deeper on NCT06462573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462573.